Previous Article | Next Article ![]()
Infection and Immunity, July 1999, p. 3548-3557, Vol. 67, No. 7
Department of Pathobiology, University of
Guelph, Guelph, Ontario N1G 2W1, Canada1;
Howard Hughes Medical Research Institute, Albert Einstein
College of Medicine, Bronx, New York 104612;
and Department of Microbiology and Immunology, Temple
University School of Medicine, Philadelphia, Pennsylvania
191403
Received 28 January 1999/Returned for modification 25 February
1999/Accepted 5 April 1999
Rhodococcus equi is a facultative intracellular
pathogen of macrophages and a cause of pneumonia in young horses
(foals) and immunocompromised people. Isolates of R. equi from pneumonic foals typically contain large, 85- or 90-kb
plasmids encoding a highly immunogenic virulence-associated protein
(VapA). The objective of this study was to determine the role of the
85-kb plasmid and VapA in the intracellular survival and
virulence of R. equi. Clinical isolates
containing the plasmid and expressing VapA efficiently replicated
within mouse macrophages in vitro, while plasmid-cured derivatives of these organisms did not multiply intracellularly. An
isolate harboring the large plasmid also replicated in the tissues of
experimentally infected mice, whereas its plasmid-cured derivative was
rapidly cleared. All foals experimentally infected with a
plasmid-containing clinical isolate developed severe
bronchopneumonia, whereas the foals infected with its plasmid-cured
derivative remained asymptomatic and free of visible lung lesions. By
day 14 postinfection, lung bacterial burdens had increased considerably
in foals challenged with the plasmid-containing clinical isolate. In
contrast, bacteria could no longer be cultured from the lungs of foals
challenged with the isogenic plasmid-cured derivative. A recombinant,
plasmid-cured derivative expressing wild-type levels of VapA failed to
replicate in macrophages and remained avirulent for both mice and
foals. These results show that the 85-kb plasmid of R. equi is essential for intracellular replication within
macrophages and for development of disease in the native host, the
foal. However, expression of VapA alone is not sufficient to restore
the virulence phenotype.
Rhodococcus equi, a
gram-positive facultative intracellular pathogen of macrophages, is one
of the most important causes of disease in foals between 1 and 5 months
of age and has emerged as a significant opportunistic pathogen of
immunosuppressed people, especially those infected with the human
immunodeficiency virus (1, 5, 11, 17). Infection in
either species is most commonly characterized by a
life-threatening pyogranulomatous pneumonia. Other, less-common
clinical manifestations of R. equi infections in
foals include ulcerative enterocolitis, colonic or mesenteric
lymphadenopathy, immune-mediated synovitis and uveitis, osteomyelitis, and septic arthritis (7). R. equi is widespread in the environment of horse-breeding
farms. Unlike most environmental isolates of R. equi,
strains isolated from pneumonic foals typically contain 85- or 90-kb
plasmids encoding a highly immunogenic, lipid-modified, virulence-associated protein (VapA) (23, 25, 29, 32, 33, 34). VapA is located on the bacterial surface, and its expression is thermoregulated, occurring between 34 and 41°C, temperatures encountered in vivo (26, 27). Because vapA has no
significant homology with other known bacterial genes, one can only
speculate on the function of the protein.
Study of the virulence of R. equi has been complicated
by the fact that typical granulomatous lung lesions have not been
consistently reproduced in any immunocompetent animal species other
than young horses. The normal murine lung can progressively clear an
inoculum of R. equi sufficient to induce severe
pneumonia in foals (36). Nevertheless, a murine intravenous
50% lethal dose infection model has demonstrated that plasmid-cured
derivatives of R. equi show a dramatic decrease in
lethality (32). However, the role of the 85-kb plasmid in
the pathogenesis of R. equi infections in foals has not
been definitively addressed. Furthermore, it remains to be established
whether VapA is a true virulence determinant or merely a marker for
virulence plasmid possession.
As the basis for the work described here, we hypothesized that the
85-kb plasmid of R. equi is essential for virulence for both mice and foals. Moreover, we questioned whether expression of VapA
alone was sufficient for virulence. We addressed the necessity of the
85-kb plasmid by infection of macrophages, mice, and foals with either
a virulent strain of R. equi containing an 85-kb
plasmid and expressing VapA or infection with its plasmid-cured
derivative. Electroporation of the plasmid-cured derivative with a
shuttle plasmid in which vapA was subcloned and expressed
and infection studies with the recombinant strain allowed us to
evaluate whether VapA expression was sufficient for virulence.
Bacteria.
R. equi 238, 2+, and
103+, originally isolated from pneumonic foals, were used.
All three strains contain an 85-kb plasmid and produce VapA (3,
12). The plasmid-cured VapA-negative isogenic derivatives of
strains 103+ and 2+ (designated strains
103 Plasmid isolation.
Plasmid DNA was isolated from
R. equi by using the Qiagen plasmid isolation system
(Qiagen, Inc., Chatsworth, Calif.). Samples were run on 0.7% agarose
gels, and plasmids were visualized by ethidium bromide staining.
Electroporation of R. equi.
Bacteria were grown
in brain heart infusion (BHI) broth to an optical density at 600 nm of
0.6 of 0.8. Bacteria were pelleted and then washed twice with an equal
volume of cold 10% glycerol in distilled water. The final resuspension
of the bacterial cells (in cold 10% glycerol) was at a 1:20 dilution
of the original culture volume. Then, 400 µl of the cells with 0.5 to
1.0 µg of DNA was placed in a prechilled 0.2-cm electroporation
cuvette (Bio-Rad, Melville, N.Y.). Electroporation was performed by
using a Gene Pulser (Bio-Rad) set at 2.5 kV, 25 µF, 1,000 Immunoblotting.
Immunoblotting for detection of VapA was
done as previously described with a mouse MAb to VapA (MAb103)
(34).
Flow cytometry.
After overnight culture at 37°C in BHI or
Mueller-Hinton broth, bacteria were washed twice and resuspended in
cation-free Dulbecco phosphate-buffered saline (PD) containing 1%
bovine serum albumin (BSA). Approximately 108 CFU of
bacteria were incubated at 4°C with a 1:2 dilution of hybridoma
culture supernatant containing MAb103. After being washed with PD
containing 1% BSA, bacteria were stained by a 45-min incubation at
4°C with a 1:100 dilution of fluorescein isothiocyanate
(FITC)-conjugated goat anti-mouse immunoglobulin G (IgG; Jackson
ImmunoResearch, West Grove, Pa.). Bacteria were then washed three times
with PD supplemented with 1% BSA, fixed in 1% paraformaldehyde, and
analyzed on an Epics Elite Flow Cytometer (Coulter Diagnostics,
Hialeah, Fla.). Negative controls included the addition of secondary
antibody without prior incubation in primary antibody and the use of an isotype-matched, irrelevant primary antibody (MAb29.1, murine anti-human Mac-1).
Assessment of shuttle vector stability during in vitro
culture.
Flow cytometry was used to assess the stability of VapA
expression by a recombinant strain of R. equi in the
presence or absence of antibiotic pressure. R. equi
103 Macrophages and macrophage cell lines.
Murine resident
peritoneal macrophages were washed from the peritoneal cavity of adult
female BALB/c mice with cold PD. Cells were resuspended in Dulbecco
modified Eagle medium (DMEM) (Gibco-BRL, Grand Island, N.Y.)
supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, and
penicillin G-streptomycin (100 U and 100 µg per ml, respectively)
(D-10). A total of 5 × 105 peritoneal cells were
placed on 13-mm-diameter glass coverslips in 24-well plates. The cells
were allowed to adhere for 1 h at 37°C, washed with warm DMEM,
and incubated an additional 2 h at 37°C in D-10 medium. At that
time the cells were washed again and then cultured overnight in
antibiotic-free DMEM supplemented with 10% FCS and 2 mM glutamine.
After washing and overnight incubation, approximately 105
cells remained per coverslip.
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Role of the 85-Kilobase Plasmid and Plasmid-Encoded
Virulence-Associated Protein A in Intracellular Survival and
Virulence of Rhodococcus equi
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
and 2
, respectively) were also used
(3). R. equi 103
/415-VapA was
created by the electroporation of strain 103
with pMH1.
pMH1 was created by subcloning a 1.6-kb vapA-containing fragment of the R. equi virulence plasmid into pYUB415
which had been previously digested with EcoRV and
BamHI. R. equi 103
/415 was
created by the electroporation of strain 103
with pYUB415
(without an insert), and this strain was used as a control in infection
experiments. pYUB415 is a 9,301-bp
Mycobacterium-Escherichia coli shuttle plasmid
kindly provided by William Jacobs (Albert Einstein College of Medicine,
Bronx, N.Y.). This vector contains an origin of replication derived
from the pAL5000 plasmid of Mycobacterium fortuitum subsp.
fortuitum (14). It also contains an E. coli origin of replication, along with ampicillin and hygromycin
resistance genes for selection in E. coli and
Mycobacterium spp., respectively. Hygromycin (150 to
175 µg/ml) is also used for selection in R. equi.
VapA expression by strain 103
/415-VapA was confirmed by
immunoblotting and flow cytometry with a monoclonal antibody (MAb)
specific for the VapA protein. Aliquots of the three strains were
stored at
70°C.
, and a
single pulse. Immediately after electroporation, 1 ml of BHI broth
supplemented with 0.5 M sucrose was added to the cuvette. Bacteria were
then incubated for 1 to 2 h at 37°C and subsequently plated on
BHI agar with 175 µg of hygromycin per ml.
/415-VapA was cultured in 10 ml of BHI broth with 150 µg of hygromycin per ml at 37°C. After a 24-h incubation, 200 µl
of culture was transferred into 10 ml of fresh BHI broth with or
without hygromycin and grown for another 24 h. The remainder of
the culture was centrifuged, and the bacterial pellet was frozen for
later flow cytometric analysis. This process was repeated every 24 h for 5 days. To detect the presence or absence of VapA on the surface
of the bacteria, frozen bacterial pellets were thawed and washed once
with PD. Pellets were then stained as described above in the
description of methods for flow cytometry.
Bacterial intracellular growth assay. Overnight broth cultures of bacteria at a density of ca. 108 CFU/ml were washed twice with PD and resuspended in phagocytosis buffer (PB), which consisted of 0.1% gelatin in equal parts of Medium 199 (Gibco) and DMEM, containing 12.5 mM HEPES. Macrophage monolayers were washed once with warm DMEM, and the medium was replaced with PB. Fresh normal mouse serum providing a source of complement components was added to the wells at a final concentration of 5%. Bacteria were added at a multiplicity of infection of 5 to 20 bacteria per macrophage. Bacterial incubation with macrophages proceeded for 30 min at 37°C, and then the monolayers were washed with PB to remove unbound bacteria. After an additional 30-min incubation period to allow bound bacteria to be internalized, the monolayers were washed again, and the medium was replaced with DMEM supplemented with 10% FCS, 2 mM glutamine, and 1 to 10 µg of gentamicin sulfate per ml. In preliminary experiments, these concentrations of gentamicin killed extracellular bacteria while minimally affecting intracellular organisms. At various times postinfection, parallel monolayers were fixed with 100% methanol (20 min at 4°C) and then repeatedly washed with PD containing 5% FCS. The fixed monolayers were incubated for 45 min with a 1:200 dilution of rabbit polyclonal anti-R. equi antiserum in PD supplemented with 5% FCS. The coverslips were then washed four times with PD with 5% FCS. The bacteria associated with the macrophage monolayers were stained by a 45-min incubation with FITC-conjugated goat anti-rabbit IgG (heavy- and light-chain specific; Jackson ImmunoResearch). The cells were then washed four more times with PD supplemented with 5% FCS and examined by fluorescence microscopy. Two hundred macrophages per coverslip were counted, and the number of bacteria associated with those cells was determined. Because of the difficulty in reliably quantifying large bacterial numbers within an individual macrophage, any cell containing more than 10 R. equi bacteria was simply scored as having 10 bacteria. The number of macrophages containing 10 or more bacteria was also determined at each time point.
Infection of mice.
Female BALB/c mice were obtained from
either the National Cancer Institute (Frederick, Md.) or Jackson
Laboratories (Bar Harbor, Maine). Mice were received at 6 weeks of age
and were used when they were between the ages of 7 and 16 weeks. In
preparation for the infection of mice, frozen aliquots of the bacterial
strains were thawed and grown for 3 h at 37°C in Mueller-Hinton
broth. Bacteria were pelleted and resuspended in PBS. Groups of mice were infected intravenously through the tail vein with either strain
103+, 103
/415, or 103
/415-VapA.
The total number of bacteria injected was confirmed retrospectively by
dilution plating of the injection stock. The inocula actually
administered were 5 × 106 CFU for strain
103+ and 2 × 106 CFU for strains
103
/415 and 103
/415-VapA. At various
times postinfection, five mice from each group were euthanized, and
their spleens and livers were removed. Each organ was placed in 10 ml
of sterile H2O and homogenized with a tissue probe
homogenizer (Tekmar, Cincinnati, Ohio). Serial 10-fold dilutions of the
homogenate were plated onto chocolate agar without antibiotic or onto
BHI agar with or without hygromycin. CFU counts were determined after
36 h of incubation at 37°C.
Infection of foals. Twenty-eight healthy mixed-breed pony foals were used in this study. These foals were used in conjunction with another study on cell-mediated immunity to R. equi. Adequate passive transfer of immunoglobulin was confirmed in foals 12 to 24 h after birth by using an enzyme-linked immunosorbent assay (ELISA) kit for semiquantitative measurement of total IgG (Cite Test; Idexx Laboratories, Westbrook, Maine). Foals were reared with their mothers on pasture and were monitored weekly for seroconversion to R. equi by ELISA as previously described (19). At 18 to 23 days of age, foals were moved with their dams to individual box stalls in an isolation facility. Criteria for inclusion in the study were normality in physical examination, lung sounds on auscultation, temperature, radiographs of the lungs, and lack of seroconversion to R. equi by ELISA. Foals meeting these criteria were randomly assigned to four experimental groups and infected 1 or 2 days after arrival in the isolation facility. There were no differences in IgG titers against R. equi between groups at the time of infection.
For experimental infection of foals, aliquots of the three bacterial strains were grown on Trypticase soy agar (TSA) plates alone (strains 103+ and 103
) or on TSA plates containing 150 µg of hygromycin per ml (strain 103
/415-VapA) for
48 h at 37°C. Bacteria were harvested with 4 ml of sterile PBS
per plate, the optical density of the resulting suspension was read at
540 nm, and the bacterial concentration was estimated from a standard
curve. The bacterial suspension was diluted with sterile PBS to a final
concentration of 5 × 107 bacteria/ml. The
concentration of the inoculum actually administered was confirmed
retrospectively by counting the CFU. Foals were sedated with 0.5 mg of
xylazine hydrochloride (Rompun; Bayer, Inc., Etobicoke, Ontario,
Canada) and 0.07 mg of butorphanol tartrate (Torbugesic; Ayerst
Laboratories, Montreal, Quebec, Canada) per kg of body weight given
intravenously. A flexible fiberoptic endoscope was used to deliver
1.25 × 109 bacteria suspended in 25 ml of sterile PBS
into both main bronchi (total dose, 2.5 × 109
bacteria in 50 ml of PBS). Eight foals were infected with strain 103+, eight foals were infected with strain
103
, six foals were infected with strain
103
/415-VapA, and six foals received only PBS and were
used as controls. The day of infection was designated as day 0. Baseline values for heart rate, respiratory rate, temperature,
fibrinogen concentration, and leukocyte count were obtained on day 0 prior to sedation. Foals were clinically assessed based on daily
complete physical examinations and twice-daily heart rate, respiratory
rate, and temperature recordings. Leukocyte counts and fibrinogen
concentrations were assessed every second day. Half of the foals in
each group (strains 103+, 103
, and
103
/415-VapA and controls) were euthanized at 3 days
postinfection, and the remaining half were euthanized at 14 days
postinfection. However, one foal infected with strain 103+
was euthanized for humane reasons at 12 days postinfection. Euthanasia was performed by intravenous administration of a lethal dose of pentobarbital sodium.
Both lungs from each animal were weighed, and the lung weight/body
weight ratio was calculated. All organs were examined grossly, and
representative samples of normal and diseased lungs, bronchial lymph
nodes, trachea, heart, thymus, kidneys, adrenals, spleen, liver,
thyroid, stomach, duodenum, ileum, jejunum, cecum, large colon,
synovial membrane, and colonic and mesenteric lymph nodes were fixed in
10% buffered formalin. The fixed tissues were embedded in paraffin,
sectioned at 10 µm, stained with hematoxylin and eosin, and examined
histologically. The pathologist was blinded as to the source of the
tissue sample. The number of viable R. equi in four
dispersed and preselected loci of both lungs was enumerated by
culturing serial dilutions of lung homogenates on TSA plates (strains
103+, 103
, and 103
/415-VapA and
controls) or TSA plates containing 150 µg of hygromycin (103
/415-VapA) per ml and counting the CFU. The eight
sites represented the craniodorsal, cranioventral, middle dorsal, and
caudodorsal parts of each lung. Results were expressed as the mean ± the standard deviation (SD) of the log10 CFU per gram of
lung tissue. In each foal infected with strain
103
/415-VapA+, 10 randomly selected colonies
were subcultured and analyzed for VapA expression by immunoblotting.
Representative samples from the spleen and liver were also homogenized
and cultured. Synovial fluid was collected from the left and right
tibiotarsal and femoropatellar joints for bacterial cultures.
Immunohistochemistry for VapA expression.
Lung samples from
foals infected with strains 103+, 103
, or
103
/415-VapA and euthanized 3 days postinfection were
collected from the cranioventral lung lobes. Frozen 5-µm sections
were placed on Superfrost Plus Slides (Fisher Scientific, Nepeon,
Ontario, Canada), air dried, and fixed in 10% buffered formalin for 10 min. Endogenous peroxidases were quenched by incubation in 0.3% H2O2 in 100% methanol. The slides were rinsed
three times in PBS, air dried, and incubated for 20 min with 10%
normal rabbit serum as the blocking agent. The sections were incubated
for 1 h with MAb103. After three rinses in PBS, the slides were
incubated for 30 min with peroxidase-conjugated rabbit anti-mouse IgG
(H+L; Jackson Immunoresearch Laboratories) diluted 1:500 in PBS. The slides were washed three times in PBS and stained by using the AEC
Chromagen Kit (Sigma, St. Louis, Mo.) according to the manufacturer's instructions. The lung sections were counterstained with 0.5% methyl
green (in 0.1 M sodium acetate) for 3 min. Ten lung sections per foal
were examined. The examiner was unaware of the experimental group.
Statistical analysis. The foal data were analyzed by using the SAS general linear model procedure (22a). Least-square means were calculated by using the general linear model procedure, and comparison between bacterial groups at each time point was done by performing a t test on the least-square means.
| |
RESULTS |
|---|
|
|
|---|
Role of the 85-kb plasmid of R. equi in
intracellular survival and replication in macrophages.
The
virulent R. equi strains 2+ and
103+ containing an 85-kb plasmid and expressing VapA,
together with their plasmid- cured isogenic derivatives 2
and 103
, were compared with respect to intracellular
survival and replication within macrophages in vitro. A previously
characterized (12) clinical isolate, strain 238, was used as
a positive control in these experiments. Murine peritoneal macrophages
were infected with R. equi for 30 min, and then
unbound bacteria were removed by repeated washing. Gentamicin
sulfate was then added to kill any remaining extracellular organisms.
We had previously determined that the traditional CFU assay was not an
accurate measure of intramacrophage rhodococcal growth due to bacterial
chaining which occurred during replication (12). Thus,
bacterial growth was monitored by using fluorescence microscopy and
counting the number of bacteria associated with 200 macrophages and the
number of macrophages containing 10 or more bacteria. The
plasmid-containing isolates 238, 103+, and 2+
replicated efficiently within macrophages, increasing in number by three- to sixfold by 48 h postinfection (Fig.
1A). Likewise, the number of macrophages
containing 10 or more bacteria increased with time postinfection (Fig.
1B). At the beginning of the experiment few, if any, of the infected
macrophages contained as many as 10 bacteria of any strain. Forty-eight
hours later, however, 56% of strain 103+-infected
macrophages, 48% of strain 238-infected macrophages, and 21% of
strain 2+-infected macrophages contained 10 or more
R. equi. In contrast to the plasmid-positive strains,
plasmid-cured derivatives failed to replicate in macrophages and
bacterial numbers remained relatively constant throughout the infection
(Fig. 1A). At 48 h few, if any, macrophages infected with the
plasmid-cured strains contained as many as 10 organisms. In addition,
bacterial growth and viability, assessed by evaluating the ability of
the bacteria to incorporate tritiated uracil as described previously
(12), yielded similar results (data not shown).
|
R. equi 103
/415-VapA expresses VapA
as well as the wild-type strain 103+ and is stable in
vitro.
A recombinant strain of R. equi was
constructed to determine if expression of plasmid-encoded VapA is
sufficient to promote replication within macrophages and virulence for
both mice and foals. R. equi 103
, the
plasmid-cured derivative of virulent R. equi
103+, was electroporated with pMH1, a shuttle vector in
which vapA was subcloned, creating the strain
103
/415-VapA. Expression of the VapA protein by the
recombinant strain 103
/415-VapA was confirmed by both
immunoblotting (Fig. 2A) and quantitative flow cytometry (Fig. 2B). Immunoblotting also verified that the recombinant protein was of the correct molecular weight (Fig. 2A). The
recombinant VapA protein was expressed on the bacterial surface
at levels comparable to that of wild-type (Fig. 2B). The flow
cytometric profile of the wild-type isolate 103+ showed
that 81% of the bacterial population expressed VapA with a mean
fluorescence intensity (MFI) of 7.4, while 89% of the recombinant strain 103
/415-VapA population expressed VapA with an MFI
of 10.3. In addition, R. equi 103
electroporated with the pYUB415 vector only (strain
103
/415) exhibited a fluorescence profile
indistinguishable from that of strain 103+ stained with an
irrelevant antibody (Fig. 2B). The expression of VapA by the
recombinant strain 103
/415-VapA, as assessed by flow
cytometric analysis, remained constant over several subsequent passages
in vitro, regardless of whether the recombinant strain was cultured in
the presence or absence of hygromycin (Table
1). Thus, in the short term, antibiotic pressure was not necessary to maintain possession of the recombinant plasmid.
|
|
Infection of macrophages with the recombinant strain that expresses
VapA.
To assess whether the expression of the VapA protein is the
sole determinant of R. equi intracellular survival
and growth potential, parallel J774A.1 macrophage
monolayers were infected with either wild-type strain
103+, its plasmid-cured derivative strain
103
, the virulence plasmid-cured, vector-electroporated
strain 103
/415, or the virulence plasmid-negative,
recombinant VapA-expressing strain 103
/415-VapA.
Whereas the wild-type isolate 103+ exhibited the ability
to replicate intracellularly, complementation of the
virulence plasmid-cured strain 103
with vapA
did not restore the capacity of this strain to grow inside macrophages
(Fig. 3). The number of bacteria
associated with macrophages, as well as the number of macrophages
containing 10 or more bacteria, increased with time postinfection for
monolayers infected with wild-type strain 103+ (Fig. 3). In
contrast, the numbers of the recombinant strain 103
/415-VapA associated with macrophages remained static
or decreased over time and were more similar to intracellular growth
curves displayed by the virulence plasmid-cured strain
103
.
|
In vivo infection of mice with R. equi
103+, 103
/415, or
103
/415-VapA.
We next determined whether expression
of VapA would affect clearance of the bacteria in vivo. Immunocompetent
BALB/c mice were intravenously infected with either R. equi 103+, 103
/415, or
103
/415-VapA, and the number of bacteria in the
livers and spleens of these mice was quantified. In preliminary studies
with a virulence plasmid-positive clinical isolate, it was
determined that bacterial burdens in infected mice increased for the
first 5 days postinfection and then decreased over the next week (data
not shown). Thus, we limited our comparisons to the first 5 days
postinfection. On day 5 postinfection, the mean bacterial counts in the
livers and spleens of mice infected with the 85-kb plasmid- containing strain 103+ were 7.51 ± 0.24 and 7.62 ± 0.15 log10/g, respectively, whereas R. equi
could not be recovered from 103
/415- and
103
/415-VapA-infected mice. Clearance of strain
103
/415-VapA was not the result of a loss of the
recombinant plasmid in vivo, since all of the bacteria recovered
on days 2 and 3 postinfection were hygromycin resistant (data not shown).
In vivo infection of foals.
Because virulence assessed by
intravenous inoculation of an R. equi-resistant species
such as mice may not necessarily reflect virulence in young horses
which are naturally challenged by the respiratory route, studies were
also performed in this native host species. To determine the role of
the 85-kb plasmid and VapA in virulence of R. equi for
foals, the virulent strain 103+ containing an 85-kb plasmid
and expressing VapA, its plasmid-cured derivative strain
103
, and the plasmid-cured derivative containing a
shuttle plasmid in which the vapA gene was subcloned (strain
103
/415-VapA) were used to intrabronchially infect pony
foals. Noninfected foals kept under the same conditions were used as controls.
or 103
/415-VapA did not differ
significantly from the baseline values or from the values of the
control foals (Fig. 4). All foals infected with strain 103+
developed mild to moderate bilateral effusion of the hocks and stifles
starting between day 6 and day 11 postinfection. Two foals infected
with strain 103+ also developed bilateral effusion of the
fetlocks and carpi. Despite effusion of multiple joints, the foals were
not lame. Neither the foals infected with strain 103
or
103
/415-VapA nor the controls developed joint effusion.
|
or 103
/415-VapA or of the PBS-treated
controls were grossly normal (Fig. 5C and D). On day 3 postinfection
the lung weight/body weight ratios of foals infected with R. equi 103+, 103
, or
103
/415-VapA were not significantly different from those
of the control foals. On day 14, the lung weight/body weight ratios of
foals infected with strain 103+ (4.58 ± 0.96%) were
significantly greater than those of the other three groups
(P < 0.0001). The ratios of foals infected with
103
(1.01 ± 0.13%) or 103
/415-VapA
(1.09 ± 0.07%) were not significantly different from those of
the control foals (1.13 ± 0.07%).
|
developed minimal
lesions: chiefly, mild atelectasis and a slight hypercellularity of the
interalveolar septa (Fig. 5G). Isolated microscopic lesions were
detected in three foals euthanized at day 14. In two of these the
lesions were microscopic foci of resolving bronchopneumonia, and in one
the lesion was a small granuloma. Mild to moderate hyperplasia of BALT
was evident in the lungs of 103
-infected foals killed 14 days after infection. The lungs of four of the foals infected with
R. equi 103
/415-VapA were
indistinguishable microscopically from those of the PBS-treated
controls. In two foals, one euthanized at day 3 and one at day
14, there were focal microscopic granulomatous lesions with rare giant
cell formation. Mild BALT hyperplasia was noted in one foal. Apart from
lung lesions, the most significant difference between foals
infected with 103+ and the three remaining experimental
groups was the development of significant suppurative synovitis in
those foals euthanized 14 days postinfection (Fig. 5H).
On day 3 postinfection, the mean number of R. equi in
the lungs of foals infected with strain 103+ was
significantly higher than in those infected with strain
103
or strain 103
/415-VapA (Fig.
6). On day 14, the strain
103+ numbers had increased significantly whereas, by
contrast, strain 103
could no longer be cultured. Small
numbers of strain 103
/415-VapA were cultured from the
lungs of only one foal infected with that strain. Both on day 3 and on
day 14, the mean bacterial numbers in the lungs of foals infected with
strain 103
were not significantly different from those of
foals infected with 103
/415-VapA (Fig. 6). R. equi was not cultured from the control foals. R. equi was cultured from the spleens of three of four foals infected
with strain 103+ and euthanized 14 days postinfection.
R. equi was also cultured from the liver of one of
those foals and from at least one joint in all four foals.
R. equi was not cultured from the spleens, livers, or
synovial fluids of foals infected with strain 103
or
strain 103
/415-VapA, and it was not cultured on day 3 from foals infected with strain 103+.
|
Strain 103
/415-VapA is stable and expresses VapA in
vivo.
To confirm that the lack of virulence of strain
103
/415-VapA was not caused by a loss of the shuttle
plasmid in vivo, the lung homogenates of foals infected with that
strain were cultured on TSA plates with or without hygromycin. On day
3, the mean bacterial count on hygromycin-containing plates (1.67 ± 0.18 log10 CFU/g of lung) was not significantly
different from that obtained on plates lacking hygromycin
(1.70 ± 0.17). On day 14, the mean bacterial count on
hygromycin-containing plates was 0.11 ± 0.16, whereas R. equi was not cultured from plates lacking
hygromycin. Ten R. equi colonies from each foal
infected with strain 103
/415-VapA and euthanized on day 3 (five from plates with hygromycin and five from plates without
hygromycin), and all of the colonies obtained from foals euthanized on
day 14 were subcultured and analyzed for VapA expression by
immunoblotting. They all produced strong VapA expression.
/415-VapA also expressed VapA
in vivo, frozen lung sections from foals euthanized on day 3 were analyzed by immunohistochemistry by using a primary MAb to VapA. 103+-infected foals had large numbers of
VapA-expressing R. equi in their lungs. The
lungs of foals infected with 103
/415-VapA were also
positive for VapA expression (Fig. 7).
VapA expression was not detected in the lungs of foals infected with strain 103
.
|
| |
DISCUSSION |
|---|
|
|
|---|
Several facultative intracellular pathogens, including
Shigella spp., Salmonella spp., and
Yersinia spp., possess large plasmids encoding a variety of
virulence loci (10, 22, 24). Among other important
contributions to virulence, these large plasmids play a role in
invasion, in intracellular survival, and/or in the ability to cause
systemic infections (10, 22, 24). The 85-kb plasmid of
R. equi is of particular interest because of its
thermoregulation of a virulence-associated protein and its likely role
in response to other environmental influences, including pH (26,
27). The present study shows that the 85-kb plasmid of
R. equi is essential for intracellular survival and
replication in macrophages (Fig. 1). We demonstrated that loss of the
plasmid affected bacterial replication in macrophages not only for
strain 103 but also for strain 2, suggesting that this is a general
effect of plasmid loss. In a recent study, strain 103+ was
somewhat resistant to phagocytosis but could survive in macrophages (8). In contrast, strain 103
was
phagocytized extensively and rapidly cleared by macrophages (8). In mice, functional T lymphocytes are absolutely
required for in vivo clearance of plasmid-containing virulent strains
of R. equi, and T lymphocyte-deficient athymic nude
mice develop a severe granulomatous pneumonia (15). In
contrast, T lymphocyte-deficient athymic nude mice can progressively
clear infection with plasmid-cured derivatives (15). These
in vivo results in mice support the in vitro findings reported here
that plasmid-cured derivatives fail to grow in macrophages and are
cleared by innate defense mechanisms such as growth inhibition or
killing by macrophages.
Because virulence in an R. equi-resistant species such
as the mouse might not necessarily reflect virulence in the natural host, we elected also to assess virulence in foals. In the present study, the plasmid-cured derivative of a virulent R. equi strain failed to induce bronchopneumonia in foals and was
rapidly cleared from the lungs within 2 weeks of infection. In
contrast, the parent plasmid-containing strain induced a severe
granulomatous pneumonia and replicated considerably in the lungs of
infected foals (Fig. 5 and 6). These results show that the 85-kb
plasmid of R. equi is absolutely required for its
virulence in foals, its only naturally occurring immunocompetent host.
However, because a concomitant chromosomal mutation in strain
103
cannot be totally excluded, irrefutable proof awaits
reintroduction of the plasmid into the plasmid-cured strain with full
restoration of virulence. The lack of phenotypic markers other than
VapA, however, makes selection of transformants extremely difficult (4). Wada et al. (35) recently reported the lack
of clinical signs and pathology at 28 and 42 days postinfection in two
foals infected with the plasmid-cured derivative of a different strain of R. equi, supporting the conclusion that the lack of
virulence of strain 103
is due to plasmid loss rather
than to chromosomal mutation. However, the present study is more
definitive and extends these findings by the use of a different strain
and considerably larger numbers of foals which were not colostrum
deprived and which were all infected at the same age rather than
between 27 and 83 days of age. In addition, this study demonstrated the
rapid clearance of the plasmid-cured strain, a finding which contrasted
with the progressive increase in numbers of the plasmid-positive parent strain.
Previous models of experimental infection of foals with R. equi have yielded equivocal results. In some studies, aerosol infection of foals with R. equi resulted in severe lesions (16), whereas in other studies administration of 1010 CFU of a virulent strain on four consecutive days failed to induce significant lesions (20). Intrabronchial administration of R. equi in saline is a more reproducible way of inducing the disease (13). The experimental infection model described here was highly reproducible, causing a disease resembling the subacute form of naturally occurring R. equi pneumonia, and will likely prove to be useful in future studies in the immunization of foals against R. equi infections. Although occasionally seen in naturally infected foals, the septic arthritis and polysynovitis observed in 103+-infected foals (Fig. 5H) had, to our knowledge, never been reproduced experimentally. The results of the present virulence study in foals concur well with in vitro intracellular survival and replication in macrophages and with organ clearance in mice, supporting the value of these two models in assessing the virulence of R. equi.
The histological lesions of foals infected with the plasmid-cured
derivative consisted mainly of mild atelectasis and hypercellularity of
the alveolar septi (Fig. 5G). However, rare mild granulomas were
observed in a few 103
- and
103
/415-VapA-infected foals. Inoculation of mice with
killed R. equi ATCC 33701 or its killed plasmid-cured
derivative both resulted in the formation of granulomas
(30). In another study, inoculation of mice with purified
mycolic acid-containing glycolipids extracted from the R. equi cell wall resulted in granuloma formation with the
glycolipids containing the longer carbon chain mycolic acid resulting
in the more severe lesions (9). Combined with the findings
reported here, these results suggest that although the 85-kb plasmid is
absolutely necessary for the pathogenicity of R. equi,
the nature of the glycolipids in the R. equi cell wall appear to be essential for the development of the typical granulomas in
vivo. Nevertheless, our study has shown that a plasmid-cured strain of
R. equi was rapidly cleared by foals, thus showing that mycolic acids and other putative virulence factors such as the polysaccharide capsule, the cholesterol oxidase, and other
phospholipases (18) are insignificant in comparison to
plasmid-mediated functions.
As opposed to foals where the 85-kb plasmid is absolutely required for virulence, opportunistic infections in immunocompromised human patients do not always result from R. equi strains containing the large plasmid and expressing VapA. In a recent study, the majority of R. equi isolates from patients with AIDS tended either to be virulent for mice, to possess 85- or 90-kb plasmids and to express VapA (24% of isolates), or to have intermediate virulence for mice and to contain one of four distinct large plasmids encoding a 20-kDa antigen related to but distinct from VapA (48% of isolates); 28% were avirulent. In contrast, most (80%) of the non-AIDS isolates were avirulent for mice, lacked plasmids, and did not express these antigens (28, 31). Since the plasmid-cured strain was rapidly cleared from the foals described here, our findings suggest that the foal is not a suitable model for R. equi pneumonic disease in immunocompromised human patients because the factors predisposing these patients to infection appear to be absent in the foal. It would be of interest, however, to examine the virulence of intermediately virulent R. equi in foals by using the reproducible model of infection described here.
This study is the first assessment of the individual role of VapA in
intracellular survival and virulence. Because of the similarities
between R. equi and Mycobacterium spp., we
correctly hypothesized that vectors used for Mycobacterium
spp. would also be stable in R. equi. The
Mycobacterium-E. coli shuttle plasmid pYUB415 in which
vapA was subcloned (strain 103
/415-VapA) was
stable in R. equi in vitro and expressed VapA to an
extent similar to that of the wild-type strain 103+ (Fig. 2
and Table 1). This shuttle plasmid was also stable in R. equi in vivo, despite the lack of hygromycin selection. Strain 103
/415-VapA expressed VapA in vivo as assessed by
immunohistochemistry on lung tissue (Fig. 7), although the level of
expression was not as strong as that observed in foals infected with
strain 103+. This reduced expression was likely the result
of the considerably lower (100-fold) bacterial numbers in their lungs
compared to those of foals infected with strain 103+.
Expression of VapA without any other plasmid-encoded products did not
restore the ability to survive or replicate in macrophages, and it did
not increase the virulence of the plasmid-cured strain for either mice
or foals. Thus, expression of VapA alone is not sufficient for
virulence (Fig. 3 and 6). However, these results do not totally rule
out a role for VapA in virulence. Creation of a vapA-deleted
strain and characterization of that mutant will determine whether VapA
is a true virulence factor. Recent sequencing adjacent to
vapA in the 85-kb plasmid of R. equi has
revealed three open reading frames with 30 to 40% overall amino acid
identity to vapA (2). All three genes were
transcribed when R. equi was cultured in vitro, and at
least one of these gene products was recognized by serum from a
naturally infected foal (2). Simultaneous expression of all
the vap-like genes may be necessary for virulence.
Although VapA alone is not sufficient for reverting a plasmid-cured
strain to virulence, several lines of evidence suggest that VapA and
possibly other Vap proteins are protective antigens. First, a MAb to
VapA and serum from horses immunized with partially purified VapA
had opsonizing activity (20, 34). Second, purified immunoglobulins obtained from horses vaccinated with partially purified VapA protected mice against intraperitoneal challenge with
R. equi when compared with mice given either a placebo
or immunoglobulins from nonimmunized horses (6). Third,
intravenous administration to foals of plasma obtained from horses
immunized with partially purified VapA resulted in significantly lower
bacterial counts in their lungs compared to foals administered plasma
with no detectable antibody to VapA (20). Finally, evidence
from mouse studies also supports the ability of VapA-enriched
antigens to produce a Th1 immune response as assessed by liver
clearance, delayed-type hypersensitivity, and immunoglobulin
isotype response (21). Because it is avirulent for foals and
expresses VapA in vivo, the recombinant strain
103
/415-VapA may prove useful as a live attenuated vaccine.
In conclusion, this study has shown that the 85-kb plasmid is essential for virulence of R. equi for foals, its natural host, and that bacterial clearance in mice and intracellular survival or replication in mouse macrophages are adequate models for assessing the virulence of R. equi. The Mycobacterium-E. coli shuttle plasmid pYUB415 is stable in R. equi both in vitro and in vivo and is a useful tool for investigating the potential virulence genes of R. equi. Expression of VapA without any other plasmid-encoded products is not sufficient for virulence. Further studies are required to identify the virulence genes of the 85-kb plasmid of R. equi and their functions, as well as the role of VapA in this infection.
| |
ACKNOWLEDGMENTS |
|---|
S. Giguère and M. K. Hondalus contributed equally to the content of this study.
This work was supported by the Natural Sciences and Engineering Research Council of Canada (J.F.P.), by the Ontario Ministry of Agriculture, Food and Rural Affairs (J.F.P.), and by the Grayson Jockey Club Research Foundation (D.M.M.). S. Giguère is the recipient of a fellowship from the Medical Research Council of Canada.
We thank Vivian Nicholson, Robert Rinfret, Meegan Larsen, and Duane Robinson for technical assistance and Kathleen Hooper-McGrevy for assistance with immunohistochemical staining.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1, Canada. Phone: (519) 824-4120, ext. 4716. Fax: (519) 767-0809. E-mail: jprescott{at}ovcnet.uoguelph.ca.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Arlotti, M., G. Zoboli, G. L. Moscatelli, G. Magnati, R. Maserati, V. Borghi, M. Andreoni, M. Libanore, L. Bonazzi, A. Piscina, and R. Ciammarughi. 1996. Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 cases. Scand. J. Infect. Dis. 28:463-467[Medline]. |
| 2. | Byrne, B. A., J. F. Prescott, G. H. Palmer, and S. A. Hines. 1998. Characterization of a virulence-associated gene family in Rhodococcus equi, abstr. P-63, p. 236. In Conference handbook of the 8th International Conference on Equine Infectious Diseases, Dubai, United Arab Emirates. |
| 3. | De la Pena-Moctezuma, A., and J. F. Prescott. 1995. Association with HeLa cells by Rhodococcus equi with and without the virulence plasmid. Vet. Microbiol. 46:383-392[Medline]. |
| 4. | De la Pena-Moctezuma, A., and J. F. Prescott. 1996. Attempts to find phenotypic markers of the virulence plasmid of Rhodococcus equi. Can. J. Vet. Res. 60:29-33[Medline]. |
| 5. | Donisi, A., M. G. Suardi, S. Casari, M. Longo, G. P. Cadeo, and G. Carosi. 1996. Rhodococcus equi infection in HIV-infected patients. AIDS 10:359-362[Medline]. |
| 6. | Fernandez, A. S., J. F. Prescott, and V. M. Nicholson. 1997. Protective effect against Rhodococcus equi infection in mice of IgG purified from horses vaccinated with virulence associated protein (VapA)-enriched antigens. Vet. Microbiol. 56:187-192[Medline]. |
| 7. | Giguère, S., and J. F. Prescott. 1997. Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals. Vet. Microbiol. 56:313-334[Medline]. |
| 8. |
Giguère, S., and J. F. Prescott.
1998.
Cytokine induction in murine macrophages infected with virulent and avirulent Rhodococcus equi.
Infect. Immun.
66:1848-1854 |
| 9. | Gotoh, K., M. Mitsuyama, S. Imaizumi, I. Kawamura, and I. Yano. 1991. Mycolic acid-containing glycolipid as a possible virulence factor of Rhodococcus equi for mice. Microbiol. Immunol. 35:175-185[Medline]. |
| 10. | Guiney, D. G., S. Libby, F. C. Fang, M. Krause, and J. Fierer. 1995. Growth-phase regulation of plasmid virulence genes in Salmonella. Trends Microbiol. 3:275-279[Medline]. |
| 11. | Harvey, R. L., and J. C. Sunstrum. 1991. Rhodococcus equi infections in patients with and without human immunodeficiency virus infection. Rev. Infect. Dis. 13:139-145[Medline]. |
| 12. |
Hondalus, M. K., and D. M. Mosser.
1994.
Survival and replication of Rhodococcus equi in macrophages.
Infect. Immun.
62:4167-4175 |
| 13. | Johnson, J. A., J. F. Prescott, and R. J. F. Markham. 1983. The pathology of experimental Corynebacterium equi infection in foals following intrabronchial challenge. Vet. Pathol. 20:440-449[Abstract]. |
| 14. | Labidi, A., C. Dauget, K. S. Goh, and H. L. David. 1984. Plasmid profiles of Mycobacterium fortuitum complex isolates. Curr. Microbiol. 11:235-240. |
| 15. | Madarame, H., S. Takai, C. Matsumoto, K. Minamiyama, Y. Sasaki, S. Tsubaki, Y. Hasegawa, and A. Nakane. 1997. Virulent and avirulent Rhodococcus equi infection in T-cell deficient athymic nude mice: pathologic, bacteriologic and immunologic responses. FEMS Immunol. Med. Microbiol. 17:251-262[Medline]. |
| 16. | Martens, R. J., R. A. Fiske, and H. W. Renshaw. 1982. Experimental subacute foal pneumonia induced by aerosol administration of Corynebacterium equi. Equine Vet. J. 14:111-116[Medline]. |
| 17. | Mosser, D. M., and M. K. Hondalus. 1996. Rhodococcus equi: an emerging opportunistic pathogen. Trends Microbiol. 4:29-33[Medline]. |
| 18. |
Prescott, J. F.
1991.
Rhodococcus equi: an animal and human pathogen.
Clin. Microbiol. Rev.
4:20-34 |
| 19. | Prescott, J. F., A. S. Fernandez, V. M. Nicholson, M. A. Patterson, J. A. Yager, L. Viel, and G. Perkins. 1996. Use of a virulence-associated protein based enzyme-linked immunosorbent assay for Rhodococcus equi serology in horses. Equine Vet. J. 28:344-349[Medline]. |
| 20. | Prescott, J. F., V. M. Nicholson, M. C. Patterson, M. C. Zandona Meleiro, A. Caterino de Araujo, J. A. Yager, and M. A. Holmes. 1997. Use of Rhodococcus equi virulence-associated protein for immunization of foals against R. equi pneumonia. Am. J. Vet. Res. 58:356-359[Medline]. |
| 21. | Prescott, J. F., M. C. Patterson, V. M. Nicholson, B. Morein, and J. A. Yager. 1997. Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice. Vet. Microbiol. 56:213-225[Medline]. |
| 22. | Sasakawa, C., J. M. Buysse, and H. Watanabe. 1992. The large virulence plasmid of Shigella. Curr. Top. Microbiol. Immunol. 180:21-44[Medline]. |
| 22a. | SAS Institute, Inc.. 1990. SAS/STAT user's guide, version 6. SAS, Cary, N.C. |
| 23. | Sekizaki, T., S. Takai, Y. Egawa, T. Ikeda, H. Ito, and S. Tsubaki. 1995. Sequence of the Rhodococcus equi gene encoding the virulence-associated 15-17-kDa antigens. Gene 155:135-136[Medline]. |
| 24. | Tabrizi, S. N., and R. M. Robins-Browne. 1992. Influence of a 70 kilobase virulence plasmid on the ability of Yersinia enterocolitica to survive phagocytosis in vitro. Microb. Pathog. 13:171-179[Medline]. |
| 25. | Takai, S., T. Anzai, Y. Sasaki, S. Tsubaki, and M. Kamada. 1993. Virulence of Rhodococcus equi isolated from lesions of infected foals. Bull. Equine Res. Inst. 30:9-14. |
| 26. | Takai, S., N. Fukunaga, K. Kamisawa, Y. Imai, Y. Sasaki, and S. Tsubaki. 1996. Expression of virulence-associated antigens of Rhodococcus equi is regulated by temperature and pH. Microbiol. Immunol. 40:591-594[Medline]. |
| 27. |
Takai, S.,
M. Iie,
Y. Watanabe,
S. Tsubaki, and T. Sekizaki.
1992.
Virulence-associated 15- to 17-kilodalton antigens in Rhodococcus equi: temperature-dependent expression and location of the antigens.
Infect. Immun.
60:2995-2997 |
| 28. | Takai, S., Y. Imai, N. Fukunaga, Y. Uchida, K. Kamisawa, Y. Sasaki, S. Tsubaki, and T. Sekizaki. 1995. Identification of virulence-associated antigens and plasmids in Rhodococcus equi from patients with AIDS. J. Infect. Dis. 172:1306-1311[Medline]. |
| 29. |
Takai, S.,
K. Koike,
S. Ohbushi,
C. Izumi, and S. Tsubaki.
1991.
Identification of 15- to 17-kilodalton antigens associated with virulence of Rhodococcus equi.
J. Clin. Microbiol.
29:439-443 |
| 30. | Takai, S., H. Madarame, C. Matsumoto, M. Inoue, Y. Sasaki, Y. Hasegawa, S. Tsubaki, and A. Nakane. 1995. Pathogenesis of Rhodococcus equi infection in mice: roles of virulence plasmids and granulomagenic activity of bacteria. FEMS Immunol. Med. Microbiol. 11:181-190[Medline]. |
| 31. |
Takai, S.,
Y. Sasaki,
T. Ikeda,
Y. Uchida,
S. Tsubaki, and T. Sekizaki.
1994.
Virulence of Rhodococcus equi isolates from patients with and without AIDS.
J. Clin. Microbiol.
32:457-460 |
| 32. |
Takai, S.,
T. Sekizaki,
T. Ozawa,
T. Sugawara,
Y. Watanabe, and S. Tsubaki.
1991.
Association between large plasmid and 15- to 17-kilodalton antigens in virulent Rhodococcus equi.
Infect. Immun.
59:4056-4060 |
| 33. |
Takai, S.,
Y. Watanabe,
T. Ikeda,
T. Ozawa,
S. Matsukura,
Y. Tamada,
S. Tsubaki, and T. Sekizaki.
1993.
Virulence-associated plasmids in Rhodococcus equi.
J. Clin. Microbiol.
31:1726-1729 |
| 34. | Tan, C., J. F. Prescott, M. C. Patterson, and V. M. Nicholson. 1995. Molecular characterization of a lipid-modified virulence-associated protein of Rhodococcus equi and its potential in protective immunity. Can. J. Vet. Res. 59:51-59[Medline]. |
| 35. | Wada, R., M. Kamada, T. Anzai, A. Nakanishi, T. Kanemaru, S. Takai, and S. Tsubaki. 1997. Pathogenicity and virulence of Rhodococcus equi in foals following intratracheal challenge. Vet. Microbiol. 56:301-312[Medline]. |
| 36. | Yager, J. A., C. A. Prescott, D. P. Kramar, H. Honnah, G. A. Balson, and B. A. Croy. 1991. The effect of experimental infection with Rhodococcus equi on immunodeficient mice. Vet. Microbiol. 28:363-376[Medline]. |
This article has been cited by other articles: